32.8% of adults free of chronic conditions showed prefrailty [Best Read]
A third of disease-free adults are prefrail; plasma proteins predict liver disease 16 years early; intracellular NAD rose 53%.
In my work as a Silicon Valley based startup executive and longevity researcher, I track the gap between what the labs are publishing and what's actually worth adding to your protocol. Here's what stood out this week — with the numbers that matter.
The biology moves faster than our readouts—this week showed intracellular NAD spiking 53% while plasma levels stayed flat, blood proteins flagging liver disease more than a decade before diagnosis, and cartilage degenerating at the molecular level while the radiographs still looked unchanged.
Whole-blood NAD rises 53% in five days, plasma NAD does not [GeroScience]
A double-blind human trial randomized 60 participants, with 50 in the primary analysis (23 on LNAD+, 27 on placebo). Five days of 2,000 mg daily NAD+ raised intracellular NAD measured in whole blood 53% by day 6 (Hedges' g = 3.66, p = 5.48 × 10⁻¹⁴), while circulating NAD measured in plasma did not move (p = 0.60). The 53% rise is predominantly a red blood cell signal, not a measurement of muscle or tissue NAD, yet the effect was clear in cells—78.3% of participants exceeded a 30% increase. Prior trials reported whole-blood NAD rises of 22–100% with nicotinamide riboside and 11–60% with nicotinamide mononucleotide, typically over 2–12 weeks. The trial ran five days, no clinical endpoints survived multiplicity correction, and it was retrospectively registered, so this is evidence that the formulation reaches cells, not evidence of benefit.
Five blood proteins spot liver fat risk up to 16 years early [Nature Aging]
A human cohort study across 50,000+ participants (Southern UK, Northern UK, EPIC-Norfolk, Southern China) identified a five-protein panel (FUOM, ACY1, KRT18, CDHR2, GGT1) that predicts metabolic dysfunction-associated steatotic liver disease up to 16 years before clinical onset, with a 16.6-year AUC of 0.756 and 5-year AUC of 0.838. This is a prediction model only—no treatment was tested and no improvement in outcomes was demonstrated. The result illustrates the core finding of this week's research: biology moves first, measurement follows, and clinical detection lags years behind both.
Among 117,163 adults free of chronic conditions, 32.8% were already prefrail [GeroScience]
A human observational study of 117,163 UK Biobank adults (mean age 53.9 ± 8.0 years, free of known chronic conditions) tested 29 physiological markers against the Fried Frailty Phenotype, finding that higher body fat %, waist-to-hip ratio, triglycerides, gamma-glutamyl transferase, alkaline phosphatase, cystatin C, HbA1c, hsCRP, and white blood cell count were associated with frailty, while higher blood pressure, lung function, bilirubin, and IGF-1 were inversely associated with frailty. Of the cohort, 1.1% were frail and 32.8% prefrail. This is observational—associations do not prove causation—but the data suggest early physiological dysregulation preceding clinically manifest chronic disease.
67.4% vs 30.0% gained physical performance, not cognition, in 3 months [GeroScience]
A human randomized trial of 188 older adults (over 75 years) with mild cognitive impairment; 46 intervention and 72 control participants were included in the analyses. The intervention group completed 3 months of home-based multicomponent exercise (3–5 days per week, based on Vivifrail), finding that 89.1% of the exercise group showed a clinically meaningful response on at least one outcome (OR = 4.82 [95% CI 1.56–14.88], p = 0.006). However, gains were concentrated in one domain: the short physical performance battery (SPPB), where 67.4% improved versus 30.0% of controls (OR 5.05, p = 0.001). No between-group differences emerged for depression (GDS), cognition (MMSE), handgrip strength, or functional ability (Barthel Index), with response rates all below 40% and p > 0.05.
Click here to share your thoughts
This newsletter is for informational purposes only and is not medical advice. Consult your physician before changing your protocol.